MTVA
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- MetaVia completed dose titration in Part 3 of the Phase 1 study of DA-1726 for obesityJul 9, 2026
- MetaVia extends Phase 1 trial of DA-1726 for obesity to 8 weeks and gives fifth weekly dose to first patientAug 6, 2025
- MetaVia doses first patient in 48 mg MAD cohort of Phase 1 trial for DA-1726 to further explore maximum tolerated dose in obesity treatmentJul 9, 2025
- MetaVia presents preclinical data showing DA-1241 adds liver protection when combined with efruxifermin at ADA's 85th Scientific SessionJun 23, 2025
- MetaVia presents data on DA-1241, a GPR119 agonist, showing both hepatoprotective and glucose-regulating effects in patients with presumed MASH, at the EASL Congress 2025.May 7, 2025